Feasibility Study of Docetaxel and Nedaplatin for Recurrent Squamous Cell Carcinoma of the Uterine Cervix

Abstract

Background: To determine a new taxane plus platinum treatment regimen for squamous cell carcinoma of the uterine cervix (CSCC), a phase I feasibility study of docetaxel (DTX) plus nedaplatin (CDGP) combination therapy was conducted. Patients and Methods: Twenty consecutive patients were enrolled into the study. The starting dose of DTX/CDGP was 60 mg/m² / 80 mg/m², every 4 weeks for at least three courses and the dose was escalated to 70 mg/m² / 100 mg/m². DTX 60 mg/m² / CDGP 100 mg/m² was also evaluated as an extra dose level. Results: Dose-limiting toxicity was granulocytopenia and the maximum tolerated dose was determined as 70 mg/m² / 100 mg/m². All 20 patients had measurable disease and a partial response was achieved in 8 (40.0%) patients. Conclusion: DTX/CDGP therapy appears to be a tolerable regimen for cervical squamous cell carcinoma, even in patients previously treated by cisplatin concurrent chemoradiotherapy. The recommended doses of DTX and CDGP were determined to be 60 mg/m² and 100 mg/m², respectively.